Join to View Full Profile
Sarah Cannon Research Institute at TN OncologyNashville, TN 37203
Dr. Garmezy is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2018 - 2021
University of MichiganResidency, Internal Medicine, 2015 - 2018
Baylor College of MedicineClass of 2015
Certifications & Licensure
TN State Medical License 2021 - 2027
TX State Medical License 2018 - 2022
MI State Medical License 2015 - 2018
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Understanding Treatment Decisions and Management for Patients with Advanced Renal Cell Carcinoma Using Hypothetical Case Studies: A Vodcast.Benjamin Garmezy, Ulka Vaishampayan
Oncology and Therapy. 2024-12-01 - Clinical Meaningfulness of an Algorithm-Based Service for Analyzing Treatment Response in Patients with Metastatic Cancer Using FDG PET/CT.Manojkumar Bupathi, Benjamin Garmezy, Michael Lattanzi, Minnie Kieler, Nevein Ibrahim
Journal of Clinical Medicine. 2024-10-16 - 9 citationsTivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 S...Toni K Choueiri, Laurence Albiges, Philippe Barthélémy, Roberto Iacovelli, Sheik Emambux
Lancet. 2024-10-05
Press Mentions
Kinnate Biopharma Inc. Receives Fast Track Designation from the U.S. Food and Drug Administration for KIN-3248, an Investigational Pan-FGFR InhibitorFebruary 14th, 2023- Kinnate Biopharma Inc. To Present Trials in Progress Poster for Its Pan-FGFR Inhibitor, KIN-3248, at the 2023 ASCO Gastrointestinal Cancers Symposium and ASCO Genitourinary Cancers SymposiumJanuary 17th, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
